AC Immune shares rise 15.19% intraday after amending Lilly deal for CHF10M upfront.

AC Immune surged 15.19% in intraday trading following an amendment to its collaboration agreement with Eli Lilly to develop Tau aggregation inhibitor small molecules for Alzheimer's disease. Under the revised terms, AC Immune secured a CHF10 million upfront payment and remains eligible for over CHF1.7 billion in future milestones, while plans to initiate Investigational New Drug-enabling studies in the first half of 2026 were confirmed. The deal extension validates the company's Morphomer platform and signals strong scientific progress in targeting intracellular Tau, driving investor optimism for the biopharma firm's pipeline potential.